Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 8, 2009, Pages 2248-2255

  Chang, Ellen T ^a,b   Shema, Sarah J ^a   Wakelee, Heather A ^b   Clarke, Christina A ^a,b   Gomez, Scarlett Lin ^a,b  

^a NORTHERN CALIFORNIA CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HUMAN; LIFESTYLE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PACIFIC ISLANDER; PRIORITY JOURNAL; SOCIAL STATUS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN AMERICANS; CALIFORNIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OCEANIC ANCESTRY GROUP; PNEUMONECTOMY; RADIOTHERAPY; SOCIOECONOMIC FACTORS;

EID: 68949107574     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0332     Document Type: Article

References (44)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2005) , National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008. Underlying mortality data provided by NCHS.
2. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer 2008;112:136-43.
3. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
5. Sekine I, Nokihara H, Yamamoto N, et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 2006;53:157-64.
6. Gandara DR, Ohe Y, Kubota K, et al. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. J Clin Oncol (Meeting Abstracts) 2004;22:7007.
7. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007;110:1532-41.
8. Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol 2008;3:216-27.
9. Ou SI, Ziogas A, Zell JA. Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): high percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity. J Clin Oncol (Meeting Abstracts) 2008;26:8004.
10. United States Census Bureau. Census 2000 summary file 4. Washington (DC): U.S. Census Bureau; 2000.
11. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of Blacks and Whites after a cancer diagnosis. JAMA 2002;287: 2106-13.
12. Blackstock AW, Herndon JE, II, Paskett ED, et al. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol 2006;24:407-12.
13. Finlay GA, Joseph B, Rodrigues CR, Griffith J, White AC. Advanced presentation of lung cancer in Asian immigrants: a case-control study. Chest 2002;122:1938-43.
14. United States Census Bureau. 2005-2007 American community survey 3-year estimates. Washington (DC): U.S. Census Bureau; 2008.
15. Fritz A, Percy C, Jack ASS, Sobin L, Parkin DM, Whelan S, editors. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
16. Gomez SL, Le GM, West DW, Satariano WA, O'Connor L. Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Am J Public Health 2003;93:1685-8.
17. NAACCR Asian/Pacific IslanderWork Group.NAACCR Asian Pacific Islander identification algorithm [NAPIIAv1.1]. Springfield (IL): North American Association of Central Cancer Registries (NAACCR); 2008.
18. NAACCR Latino Research Work Group. NAACCR guideline for enhancing Hispanic/Latino identification: revised NAACCR Hispanic/Latino identification algorithm [NHIA v2]. Springfield (IL): North American Association of Central Cancer Registries (NAACCR); 2005.
19. Yost K, Perkins C, Cohen R, Morris C,WrightW. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2001;12:703-11.
20. Block G, Matanoski GM, Seltser RS. A method for estimating year of birth using social security number. Am J Epidemiol 1983;118:377-95.
21. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-6.
22. Gomez SL, Quach T, Horn-Ross PL, et al. Uncovering hidden disparities: disaggregating breast cancer incidence rates in Asian women by immigrant status. Am J Public Health. In press.
23. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-802.
24. Wakelee HA,WangW, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006;1:441-6.
25. Srinivasan S, Guillermo T. Toward improved health: disaggregating Asian American and Native Hawaiian/Pacific Islander data. Am J Public Health 2000;90:1731-4.
26. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008;58:9-31.
27. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-10.
28. Pickett KE, Pearl M. Multilevel analyses of neighbourhood socioeconomic context and health outcomes: a critical review. J Epidemiol Community Health 2001;55:111-22.
29. Egusa G, Yamane K. Lifestyle, serum lipids and coronary artery disease: comparison of Japan with the United States. J Atheroscler Thromb 2004;11:304-12.
30. Nakanishi S, Okubo M, Yoneda M, Jitsuiki K, Yamane K, Kohno N. A comparison between Japanese-Americans living in Hawaii and Los Angeles and native Japanese: the impact of lifestyle westernization on diabetes mellitus. Biomed Pharmacother 2004;58:571-7.
31. An N, Cochran SD, Mays VM, McCarthy WJ. Influence of American acculturation on cigarette smoking behaviors among Asian American subpopulations in California. Nicotine Tob Res 2008;10:579-87.
32. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-44.
33. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
34. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-500.
35. Mok T. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Abstract LBA2. Presentation at the 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, September 12-16, 2008.
36. Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007;2:430-9.
37. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008;14:3860-6.
38. Sone T, Kasahara K, Kimura H, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 2007;109:1836-44.
39. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer 2008;112:2011-20.
40. Goodman MT, Kolonel LN, Wilkens LR, Yoshizawa CN, Le Marchand L. Smoking history and survival among lung cancer patients. Cancer Causes Control 1990;1:155-63.
41. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007;132:185-92.
42. Sridhar KS, Raub WA, Jr. Present and past smoking history and other predisposing factors in 100 lung cancer patients. Chest 1992;101:19-25.
43. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990;8:1402-7.
44. S. 3187. A bill to establish a comprehensive interagency response to reduce lung cancer mortality in a timely manner: Lung Cancer Mortality Reduction Act of 2008. 110th Congress. June 25, 2008.